4
Changes in Ownership
GeneDx Holdings Corp. Filed Acc 0001689575-26-000010
CHIEF EXECUTIVE OFFICER sold 25,459 shares at an average $78.61 ($2,001,371)
- CHIEF EXECUTIVE OFFICER acquired 47,684 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-03 | Grant or award | +47,684 | 64,142 | D | ||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-04 | Sale | −5,861 | $77.63 | $454,967 | 58,281 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-04 | Sale | −10,465 | $78.61 | $822,621 | 47,816 | D |
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-04 | Sale | −9,133 | $79.25 | $723,783 | 38,683 | D |
| Derivatives | |||||||
| Stueland Katherine CHIEF EXECUTIVE OFFICER | 2026-03-03 | Grant or award · Restricted Stock Unit | +40,418 | 40,418 | D | ||
| Open-market sales · 25,459 sh · avg $78.61 · $2,001,371 | |||||||
Loading xslF345X05/form4-03052026_100322.xml…